LUCDMEDIUM SIGNALFINANCIAL10-K

LUCD shows substantially higher revenue growth but deepening losses amid enhanced cybersecurity governance disclosures.

The company demonstrates strong commercial momentum with meaningful revenue expansion, yet this growth comes at the cost of significantly larger net losses. The substantial reduction in interest expense suggests improved debt management, while enhanced cybersecurity risk oversight language indicates strengthened governance frameworks in response to regulatory expectations.

Comparing 2026-03-25 vs 2025-03-24View on EDGAR →
FINANCIAL ANALYSIS

LUCD delivered substantially higher revenue growth while dramatically reducing interest expense by 93.7%, indicating strong operational progress and improved capital efficiency. However, net losses deepened by 27.4% to $58.0M, suggesting the company is still investing heavily in growth initiatives. The balance sheet strengthened with current assets growing 49% and cash increasing 18.3% to $22.4M, while liabilities rose more modestly at 16.5%, creating a more favorable liquidity position for continued operations.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-93.7%
$416K→$26K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
+79%
$2.4M→$4.3M

Strong top-line growth of 79% — accelerating demand or successful expansion into new markets.

Current Assets
Balance Sheet
+49%
$25.1M→$37.5M

Current assets grew 49% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-33.4%
$296K→$197K

Capex reduced 33.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
+31.7%
$30.7M→$40.4M

Asset base grew 31.7% — expansion through organic growth, acquisitions, or capital deployment.

Net Income
P&L
-27.4%
-$45.5M→-$58.0M

Net income declined 27.4% — review whether driven by operations, interest costs, or non-recurring items.

Current Liabilities
Balance Sheet
+21.5%
$23.5M→$28.6M

Current liabilities rose 21.5% — increased short-term obligations, watch current ratio.

Cash & Equivalents
Balance Sheet
+18.3%
$18.9M→$22.4M

Cash grew 18.3% — improving liquidity position supports investment and shareholder returns.

Total Liabilities
Balance Sheet
+16.5%
$25.3M→$29.5M

Liabilities increased 16.5% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-24
ADDED
false --12-31 FY 2025 Our board administers its cybersecurity risk oversight function directly through our audit committee.
Our audit committee has primary responsibility for overseeing our risk assessment and risk management policies (including with respect to cybersecurity matters).
Our audit committee regularly discusses with management, counsel, and auditors the Company s major risk exposures.
This includes potential financial impact on the Company and the steps taken to monitor and control those risks.
Additionally, our board is informed regarding the risks facing the Company and coordinates with management and our cybersecurity team to ensure our board receives regular risk assessment updates from management.
Our board administers its cybersecurity risk oversight function directly through our audit committee.
Our audit committee has primary responsibility for overseeing our risk assessment and risk management policies (including with respect to cybersecurity matters).
Our audit committee regularly discusses with management, counsel, and auditors the Company s major risk exposures.
This includes potential financial impact on the Company and the steps taken to monitor and control those risks.
Additionally, our board is informed regarding the risks facing the Company and coordinates with management and our cybersecurity team to ensure our board receives regular risk assessment updates from management.
REMOVED
As of December 31, 2024 and March 20, 2025 there were 66,969,390 and 90,753,851 , respectively, shares of the registrant s Common Stock, par value $ 0.001 per share, issued and outstanding (with such number of shares inclusive of shares of common stock underlying unvested restricted stock awards granted under the Lucid Diagnostics Inc.
Securities and Exchange Commission within 120 days after the year ended December 31, 2024 .
Background and Overview Lucid Diagnostics is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease ( GERD ), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma ( EAC ).
EsoGuard is a bisulfite-converted targeted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck.
It quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1).
Two independent clinical validation case control studies funded by the National Institute of Health utilized were performed using upper endoscopy with biopsies as the diagnostic comparator and confirmed EsoGuard accurately identifies BE.
A pooled analysis of both studies demonstrated 84% sensitivity (95% confidence interval ( CI ) 76-90%), for detection of BE, and 86% specificity (95% CI 81-91%).
Positive predictive value (PPV) and negative predictive value (NPV) were calculated using a BE prevalence of 10.6% published in a meta-analysis of U.S patients with GERD.
This resulted in a PPV of approximately 42% and NPV of around 98% .
EsoCheck is an FDA 510(k) and CE Mark cleared noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in a less than five-minute office procedure.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →